N Stage Disease in Patients with Non–Small Cell Lung Cancer: Efficacy of Quantitative and Qualitative Assessment with STIR Turbo Spin-Echo Imaging, Diffusion-weighted MR Imaging, and Fluorodeoxyglucose PET/CT

Ohno, Yoshiharu; Koyama, Hisanobu; Yoshikawa, Takeshi; Nishio, Motohiro; Aoyama, Nobukazu; Onishi, Yoshiaki; Takenaka, Daisuke; Matsumoto, Shinsuke; Maniwa, Yoshimasa; Nishio, Wataru; Nishimura, Yoshihiro; Itoh, Tomoo; Sugimura, Kazuro

doi:10.1148/radiol.11110281

Cited by 92 publications

(100 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In recent years, other imaging modalities or intraoperative diagnostic procedures are being developed to obtain more accurate diagnosis of lymph node metastasis in lung cancer patients. Ohno et al 18) evaluated the diagnostic capability of short inversion time inversion-recovery (STIR) turbo spin-echo (SE) imaging in nodal assessment in patients with NSCLC, and they concluded that STIR turbo SE imaging is more sensitive and/or more accurate than FDG-PET/CT. 18) Inoue et al 19) suggested the potential clinical utility of one-step nucleic acid amplification (OSNA) assay, which was an automated rapid molecular diagnostic method using optimal mRNA marker, for intraoperative rapid and accurate diagnosis of nodal status in lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological Characteristics of Lung Adenocarcinoma with Unexpected Lymph Node Metastasis

Haruki

Wakahara

Matsuoka

et al. 2017

ATCS

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Clinicopathological Characteristics of Lung Adenocarcinoma with Unexpected Lymph Node Metastasis

Haruki

Wakahara

Matsuoka

et al. 2017

ATCS

View full text Add to dashboard Cite

“…15 and 16). According to previously published results (Fujimoto et al 1995;Takenaka et al 2002;Ohno et al 2004dOhno et al , 2007cOhno et al , 2011bYi 2008;Morikawa et al 2009), sensitivity of quantitatively and qualitatively assessed STIR turbo SE imaging ranged, on a per-patient basis, from 83.7 to 100.0%, specificity from 75.0 to 93.1%, and accuracy from 86.0 to 92.2%, and these values are equal to or higher than those for CE-CT, FDG-PET, or PET/CT. Yet another study showed that the quantitative and qualitative sensitivity, specificity, and accuracy of STIR turbo SE imaging were not significantly different from those of FDG-PET/CT.…”

Section: Mr Assessment Of N Classificationmentioning

confidence: 83%

Lung Cancer

Ohno¹,

Koyama²,

Dinkel³

2016

MRI of the Lung

Self Cite

View full text Add to dashboard Cite

Since the publication of the Radiologic Diagnostic Oncology Group Report (RDOG) in 1991, the clinical application of pulmonary magnetic resonance (MR) imaging to patients with lung cancer has been limited. MDCT has been much more widely available for staging of lung cancer in clinical situations. Traditionally, FDG-PET or PET/CT is the only modality that reveals biological glucose metabolism of lung cancer, and ventilation and/or perfusion scintigraphy is the only modality that demonstrates pulmonary function. However, recent advances of MR systems and utilization of contrast media make it possible to overcome the limitation of chest MR imaging. Therefore, in the last years, several investigators have demonstrated the significant comprehensive potential of MR imaging to substitute for MDCT and nuclear medicine examinations in lung cancer staging. Currently, MR imaging in lung cancer patients can be applied for (1) detection of pulmonary nodules, (2) characterization of solitary pulmonary nodules, and (3) assessment of TNM classification in routine clinical practice. We believe that further basic studies, as well as clinical applications of newer MR techniques, will play an important role in the future management of patients with lung cancer including MRI.

show abstract

“…It has primarily been used clinically for brain disorders, particularly for the early detection of ischemic stroke or infarction (33)(34)(35)(36). Numerous studies have put forward DWI as a new and valuable cancer imaging biomarker for detection, diagnosis, staging, detecting metastasis or relapse, and assessing treatment response (30)(31)(32)(37)(38)(39)(40)(41)(42)(43)(44). Studies have also demonstrated that, for malignancy imaging, the quantitative analysis of ADC and the standard uptake value (SUV) in fluorodeoxyglucose positron emission tomography (FDG PET)/CT are inversely correlated (37)(38)(39)(40)(41)(42).…”

Section: Discussionmentioning

confidence: 99%

“…Numerous studies have put forward DWI as a new and valuable cancer imaging biomarker for detection, diagnosis, staging, detecting metastasis or relapse, and assessing treatment response (30)(31)(32)(37)(38)(39)(40)(41)(42)(43)(44). Studies have also demonstrated that, for malignancy imaging, the quantitative analysis of ADC and the standard uptake value (SUV) in fluorodeoxyglucose positron emission tomography (FDG PET)/CT are inversely correlated (37)(38)(39)(40)(41)(42). ADC and SUV play complementary roles in the provision of functional information concerning cancer, which can now be successfully applied in head and neck cancers, after overcoming the motion artifacts from swallowing or respiration and susceptibility artifacts due to air/soft tissue/ bone interfaces (38)(39)(40).…”

Section: Discussionmentioning

confidence: 99%

Differentiation between Graves' disease and painless thyroiditis by diffusion-weighted imaging, thyroid iodine uptake, thyroid scintigraphy and serum parameters

Meng

Zhang

Sun

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The aim of the present study was to assess the apparent diffusion coefficient (ADC) in diffusion-weighted imaging (DWI), thyroid radioactive iodine uptake (RAIU), thyroid scintigraphy and thyrotropin receptor antibody (TRAb) levels in the differential diagnosis between Graves' disease (GD) and painless thyroiditis (PT). A total of 102 patients with GD and 37 patients with PT were enrolled in the study. DWI was obtained with a 3.0-T magnetic resonance scanner, and ADC values were calculated. RAIU and thyroid scintigraphy were performed. Tissue samples were obtained from patients with GD (6 cases) following thyroidectomy, and from patients with PT (2 cases) following biopsy. Receiver operating characteristic (ROC) curves were drawn, optimal cut-off values were selected, and the sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) were assessed. It was found that the ADC, TRAb and RAIU were significantly higher in GD than in PT (P<0.05). ROC curves showed areas under the curves for RAIU, ADC and TRAb that were >0.900. RAIU was the reference method. Sensitivity, specificity, accuracy, PPV and NPV were 96. 078, 91.892, 95.000, 97.059 and 89.474% for ADC, and 88.235, 75.676, 84.892, 90.909 and 70.000% for TRAb, after the optimal thresholds of 1.837x10 -3 mm 2 /sec and 1.350 IU/ml were determined respectively. Histopathology showed that tissue cellularity in PT was much higher than in GD due to massive lymphocytic infiltration. The results of the present study indicate that RAIU, ADC and TRAb are of diagnostic value for differentiating between GD and PT. DWI has great potential for thyroid pathophysiological imaging because it reflects differences in tissue cellularity between GD and PT.

show abstract

N Stage Disease in Patients with Non–Small Cell Lung Cancer: Efficacy of Quantitative and Qualitative Assessment with STIR Turbo Spin-Echo Imaging, Diffusion-weighted MR Imaging, and Fluorodeoxyglucose PET/CT

Abstract: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.11110281/-/DC1.

Cited by 92 publications

References 28 publications

Clinicopathological Characteristics of Lung Adenocarcinoma with Unexpected Lymph Node Metastasis

Clinicopathological Characteristics of Lung Adenocarcinoma with Unexpected Lymph Node Metastasis

Lung Cancer

Differentiation between Graves' disease and painless thyroiditis by diffusion-weighted imaging, thyroid iodine uptake, thyroid scintigraphy and serum parameters

Contact Info

Product

Resources

About